Consumer medicine information

MSN Cabazitaxel 60 mg/1.5 mL Concentrate for infusion

Cabazitaxel

BRAND INFORMATION

Brand name

MSN Cabazitaxel

Active ingredient

Cabazitaxel

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using MSN Cabazitaxel 60 mg/1.5 mL Concentrate for infusion.

What is in this leaflet


This leaflet answers some common questions about MSN Cabazitaxel.
It does not contain all the available information. It does not take the place of talking to your doctor.
All medicines have risks and benefits. Your doctor has weighed the risks of you being given this medicine against the benefits they expect it will have for you.
If you have any concerns about being given this medicine, ask your doctor.
Keep this leaflet in a safe place as you may need to read it again

What MSN Cabazitaxel is used for


The name of your medicine is MSN Cabazitaxel. It belongs to a group of medicines called 'taxanes' used to treat cancers. MSN Cabazitaxel is used to treat prostate cancer that has progressed after having had other chemotherapy. It works by stopping cells from growing and multiplying.
Ask your doctor if you have any questions about why it has been prescribed for you.
This medicine is only available with a doctor's prescription.
There is no evidence that this medicine is addictive.

Before you are given MSN Cabazitaxel


Do not receive MSN Cabazitaxel if:

  • the number of your white blood cells is too low (neutrophil counts of 1,500 per cubic millimetre, or less - your doctor will advise you on this),
  • you have a liver disease
  • you are pregnant or breastfeeding
  • you have recently received or are about to receive a vaccine against yellow fever.

Do not receive MSN Cabazitaxel if you are allergic to it or any of the ingredients listed at the end of this leaflet.
Some symptoms of an allergic reaction include skin rash, itching, shortness of breath or swelling of the face, lips or tongue, which may cause difficulty in swallowing or breathing.
Do not receive MSN Cabazitaxel if you are pregnant or intend to become pregnant.
MSN Cabazitaxel may affect your developing baby if you are given MSN Cabazitaxel during pregnancy. If your partner is pregnant or is planning on becoming pregnant, ensure to use a condom.
The use of effective contraception in male patients with partners who may become pregnant is recommended during treatment and for 6 months after the final treatment is given. MSN Cabazitaxel might be present in your semen. Therefore, the use of a condom is always recommended during sexual intercourse.
Do not receive MSN Cabazitaxel if you are breastfeeding or planning to breastfeed.
MSN Cabazitaxel could pass into breast milk and there is a possibility your baby may be affected.
Do not give MSN Cabazitaxel to a child or adolescent.
Do not receive MSN Cabazitaxel after the expiry date (EXP) printed on the vial.
If you receive it after the expiry date has passed, it may not work as well.
Do not receive MSN Cabazitaxel if the packaging is damaged or shows signs of tampering.

Before you are given MSN Cabazitaxel


Tell your doctor if:
  • you have allergies to the ingredients listed at the end of this leaflet
  • you are taking other medicines including medicines used to prevent blood clots and oral nonsteroidal anti-inflammatories (NSAIDS).

Tell your doctor if you are pregnant or intend to become pregnant.
Like most medicines of this kind, MSN Cabazitaxel is not recommended to be used during pregnancy. Your doctor will discuss the risks and benefits of receiving MSN Cabazitaxel if you are pregnant.
Tell your doctor if you are breastfeeding or planning to breastfeed.
It is not known whether MSN Cabazitaxel passes into breast milk. Your doctor will discuss the risks and benefits of receiving MSN Cabazitaxel if you are breastfeeding or planning to breastfeed.
Tell your doctor if you have or have had any medical conditions, especially the following:
  • a fever (during treatment with MSN Cabazitaxel, it is more likely that your white blood cell count may be reduced). Your doctor will monitor your blood and general condition for signs of infections.
  • any allergies
  • lung, liver or kidney problems
  • any stomach problems past or present (including ulcers)
  • severe or long-lasting diarrhoea, nausea or vomiting. Any of these events could cause dehydration. Your doctor may need to treat you.
  • if you have a feeling of numbness, tingling, burning or decreased sensation in your hands or feet
  • if you have any bleeding from the gut that may cause changes in the colour of your stool or stomach pain.

This medicine contains 13% w/w ethanol (alcohol), equivalent to 14 ml of beer or 6 ml of wine. To be taken into account if:
  • if suffer from alcoholism
  • have a liver disease
  • have epilepsy/seizures

Tell your doctor if you plan to have surgery.
If you have not already told your doctor about any of the above, tell them before you are given MSN Cabazitaxel.

Taking other medicines


Tell your doctor if you are taking any other medicines including herbal supplements and vitamins and those that you buy without a prescription from your pharmacy, supermarket or health food store.
This is because some medicines can affect the way MSN Cabazitaxel works or MSN Cabazitaxel can affect how other medicines work. These include:
  • medicines used to treat bacterial, fungal or viral infections (e.g. clarithromycin, ketoconazole, rifampicin)
  • medicines used to treat seizures or epilepsy (e.g. carbamazepine, phenobarbital, phenytoin)
  • herbal remedy for depression and other conditions (St John's Wort (Hypericum perforatum)

Talk to your doctor before getting vaccinations while you are receiving MSN Cabazitaxel.
Your doctor or pharmacist has more information on medicines to be careful with or to avoid while being given MSN Cabazitaxel.

How MSN Cabazitaxel is given

How much to be given


The dose will depend on your height and weight. Your doctor will calculate your body surface area in square meters (m2) and will determine the dose you should receive.
The standard dose of MSN Cabazitaxel is 20 mg per square metre. Your doctor may decide on an alternative dose depending on your condition.

Additional medication


As part of your treatment for prostate cancer, you will also take an oral corticosteroid medicine (prednisone or prednisolone) daily.
Half an hour before you receive MSN Cabazitaxel, you will be given the following medications to reduce your chance of developing an allergic reaction or nausea:
  • antihistamine (diphenhydramine or equivalent)
  • corticosteroid (dexamethasone or equivalent)
  • H2 antagonist (ranitidine or equivalent)
  • anti-nausea medication (if required)

How MSN Cabazitaxel is given


MSN Cabazitaxel will be given by infusion into one of your veins (intravenous use). The infusion will last approximately 1 hour during which you will be in the hospital.

Duration of treatment


You should usually receive your infusion once every 3 weeks.
Each 3 week period is called one cycle of chemotherapy. Your doctor will decide how many of these cycles you will need.
If you have any further questions about how you will receive this medicine, ask your doctor, pharmacist or nurse.

If you receive too much (overdose)


As MSN Cabazitaxel is given to you under the supervision of your doctor, it is very unlikely that you will receive too much. However, if you experience any unexpected or worrying side effects after being given MSN Cabazitaxel immediately telephone your doctor, or the Poisons Information Centre (telephone Australia 13 11 26) or go to Accident and Emergency at your nearest hospital.
If you receive too much MSN Cabazitaxel, you may experience one or more of the following symptoms: fever, nausea, diarrhoea, vomiting, constipation, abdominal pain, including upper abdominal pain, indigestion, and reflux.

While you are being given MSN Cabazitaxel

Things you must do:


Use a condom during sex if your partner is or could become pregnant. MSN Cabazitaxel could be present in your semen and may affect the foetus. You are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because MSN Cabazitaxel may alter male fertility.
If your partner becomes pregnant while you are being given this medicine, tell your doctor immediately.
Tell all the doctors, dentists and pharmacists who are treating you that you are being given MSN Cabazitaxel.
If you are about to be started on any new medicine, tell your doctor and pharmacist that you are being given MSN Cabazitaxel.
If you plan to have surgery that needs a general anaesthetic, tell your doctor or dentist that you are being given this medicine.

Things you must not do


Do not receive more than the recommended dose unless your doctor tells you to.
Do not stop using MSN Cabazitaxel without checking with your doctor.
If you do not complete the full course prescribed by your doctor, MSN Cabazitaxel may not work as well as it's supposed to.

Things to be careful of


Be careful driving or operating machinery until you know how MSN Cabazitaxel affects you.
MSN Cabazitaxel may cause side effects such as fatigue or dizziness that may affect your ability to drive and use machinery. Make sure you know how you react to MSN Cabazitaxel before you drive a car, operate machinery, or do anything else that could be dangerous if you feel dizzy or fatigued.
If you experience these symptoms, do not drive or use any tools or machines until they have fully resolved.

Side Effects


MSN Cabazitaxel helps most people with prostate cancer, but it may have unwanted side effects in some people.
All medicines have some unwanted side effects. Sometimes they are serious, but most of the time they are not. Your doctor or pharmacist has weighed the risks of using this medicine against the benefits they expect it will have for you.
Tell your doctor, nurse or pharmacist as soon as possible if you do not feel well while you are being given MSN Cabazitaxel.
Do not be alarmed by this list of possible side effects.
You may not experience any of them.
If any of the following happen while you are being given MSN Cabazitaxel in the hospital/clinic, MSN Cabazitaxel should be stopped immediately. Tell your doctor or nurse immediately. If you are outside of the hospital/clinic go to Accident and Emergency at your nearest hospital:

  • swelling of the face, lips, mouth or throat, which may cause difficultly in swallowing or breathing.
  • hives
  • fainting
  • yellowing of the skin and eyes (jaundice)

These are very serious side effects. If you have them, you may have had a serious allergic reaction to MSN Cabazitaxel. You may need urgent medical attention or hospitalisation.
These side effects are very rare.
See a doctor immediately if you notice any of the following side effects:
  • fever (high temperature). This is very common (affects more than 1 in 10 patients)
  • severe loss of body fluids (dehydration). This is common (affects less than 1 in 10 patients).
    This can occur if you have severe diarrhoea (increase of more than 4 or more stools more than usual a day) or long-lasting diarrhoea, or fever, or if you are vomiting.

Tell your doctor, nurse or pharmacist if you notice any of the following:
Very common side effects (affects more than 1 in 10 patients):
  • feeling tired, weak or lack of energy
  • symptoms of anaemia like tiredness, and inability to perform daily tasks (due to a decrease in the number of red blood cells)
  • increased bleeding (due to a decrease in the number of platelets)
  • loss of appetite (anorexia)
  • alteration in sense of taste
  • shortness of breath
  • cough
  • stomach upsets including nausea, vomiting and diarrhoea, constipation
  • abdominal pain
  • short term hair loss (in most cases normal hair growth should return after treatment has stopped)
  • back pain
  • joint pain
  • blood in the urine

Common side effects (affects less than 1 in 10 patients):
  • urinary tract infection
  • fever and infection (associated with a reduction of white blood cells)
  • feeling of numbness, tingling, burning or decreased sensations in hands and feet
  • dizziness
  • headache
  • decrease or increase in blood pressure
  • uncomfortable feeling in the stomach or belching after eating.
  • gastro-oesophageal reflux or heartburn
  • stomach pain
  • haemorrhoids
  • muscle spasm
  • pain when passing urine
  • urinary incontinence
  • sores in the mouth or on the lips
  • high blood sugar
  • low blood potassium
  • rapid or irregular heartbeat
  • kidney disease or problems
  • ringing in the ear
  • trouble with balance
  • blood clot in the leg
  • pain in mouth or throat
  • rectal bleeding
  • redness of skin
  • skin infections
  • skin feeling hot or flushed
  • muscle discomfort, aches or pain
  • swelling of the feet or legs
  • lung infection
  • chills

Inflammation of the bladder may also occur if you have previously received radiation therapy. Tell your doctor, nurse or pharmacist if you have burning sensation when passing urine.
Tell your doctor, nurse or pharmacist if you notice anything else that is making you feel unwell.
Other side effects not listed above may occur in some patients.
Ask your doctor, nurse or pharmacist to answer any questions you may have if you experience any side effects.

After being given MSN Cabazitaxel


If you have any queries about any aspect of your medicine, or any questions regarding the information in this leaflet, discuss them with your doctor, nurse or pharmacist.

Storage


MSN Cabazitaxel is stored in the pharmacy or on the ward. Do not store at home.

Product description

What MSN Cabazitaxel looks like


One pack of MSN Cabazitaxel consists of:
  • One 15 mL glass vial of concentrate (which is a colourless to pale yellow thick solution)
  • One 15 mL glass vial of diluent (which is a clear and colourless solution)

Ingredients


Active Ingredient:
The active substance is cabazitaxel. One ml of concentrate contains 40mg cabazitaxel. Each vial of concentrate contains 60mg cabazitaxel.
Inactive Ingredients:
The other ingredients are polysorbate 80 in the concentrate and ethanol 96% and water for injections in the diluent.
MSN Cabazitaxel does not contain gluten, sucrose, lactose, tartrazine or any other azo dyes.

Sponsor


Reach Pharmaceuticals Pty Ltd
Ground Floor, Corporate One,
84 Hotham Street,
Preston VIC 3074
AUSTRALIA
This leaflet was prepared in December 2021.

BRAND INFORMATION

Brand name

MSN Cabazitaxel

Active ingredient

Cabazitaxel

Schedule

S4

 

1 Name of Medicine

Cabazitaxel.

2 Qualitative and Quantitative Composition

Cabazitaxel is a white to off-white powder with a molecular formula of C45H57NO14 and a molecular weight of 835.93. It is lipophilic, practically insoluble in water, freely soluble in acetone and soluble in dichloromethane.
Cabazitaxel belongs to the taxanes class. It is prepared by semi synthesis with a precursor extracted from yew needles.
Chemical name of cabazitaxel is (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

MSN Cabazitaxel 60 mg/1.5 mL concentrate is a sterile, colourless to pale yellow viscous solution and is available in single-use vials containing 60 mg (1.5 mL) cabazitaxel and 1.56 g polysorbate 80.
Each mL of concentrate contains 40 mg cabazitaxel (anhydrous) and 1.04 g polysorbate 80.
Diluent for MSN Cabazitaxel is a clear, colourless, sterile, and non-pyrogenic, solution containing 13% (w/w) ethanol in water for injection, 4.5 mL.

4 Clinical Particulars

4.9 Overdose

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).
Signs and symptoms. The anticipated complications of overdose would be exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders.
Management. There is no known antidote to cabazitaxel. In case of overdose, the patient should be kept in a specialised unit and closely monitored. Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken.

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Cabazitaxel was negative in the bacterial reverse mutation (Ames) test. Cabazitaxel was not clastogenic in an in vitro test in human lymphocytes (no induction of structural chromosomal aberrations) but it increased the number of polyploid cells and it induced an increase of micronuclei in the in vivo micronucleus test in rats. However, these genotoxicity findings are inherent to the pharmacological activity of the compound (inhibition of tubulin depolymerisation) and have been observed with other compounds with the same pharmacological activity.
Carcinogenicity. Long-term animal studies have not been performed to evaluate the carcinogenic potential of cabazitaxel.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSCBZITA.gif Chemical name: (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate.
Molecular Formula: C45H57NO14 (free base).
Molecular Weight: 835.93.
CAS number. 183133-96-2.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/MSNCABST.gif